- Postoperative radiotherapy (PORT) in stage IIIA NSCLC is associated with significantly better OS in patients with N2 disease, especially those with ≥6 positive lymph nodes.
- However, PORT was associated with significantly higher mortality in patients with N1 disease in this study.
Why this matters
- Research on OS with PORT has yielded conflicting results.
- 5168 patients with resected stage IIIA NSCLC from the Surveillance, Epidemiology, and End Results database were treated with PORT (n=1711) or not (n=3457).
- Funding: None disclosed.
- No significant difference in OS in N0 disease.
- Significantly better OS with postoperative chemotherapy (POCT) alone in N2 disease vs POCT+PORT:
- 56 vs 32 months (P=.0004).
- Patients with N2 disease and ≥6 positive lymph nodes who received PORT had significantly better OS than those who did not:
- 31 vs 22 months (P<.0001>
- These patients also had better OS with POCT+PORT vs POCT alone:
- 32 vs 25 months (P=.009).
- PORT was associated with significantly better OS in patients with N2 disease and
- 47 vs 41 months (P=.002).
- Benefit not seen with POCT+PORT.